No. 035 · Mind · Sleep Peptide
DSIP
Also known as: Delta sleep-inducing peptideEmideltideDeltaran
- Not FDA approved
- WADA — not listed
- Nonpolar 6
- Polar 1
- Negative charge 2
Each dot is a residue placed around the ring from N- to C-terminus; its distance from the centre reflects its chemistry.
Evidence
- D In vitro
- C Animal
- B Human pilot
- A RCT
- S Approved
TIER A — At least one published randomized controlled trial in humans.
Small double-blind, placebo-controlled trials in chronic insomnia (e.g. Bes et al. 1992, n=16) found weak or no meaningful benefit; registered as a medicine in Russia but not FDA/EMA-approved.
Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.
At a glance
- Residues
- 9 amino acids, N→C
- Molecular weight
- 848.8 Da
- Formula
- C35H48N10O15
- Discovered
- 1977 Isolated from rabbit blood during induced sleep and characterized by Schoenenberger and Monnier (PNAS 1977).
- Routes studied
- Subcutaneous, Intramuscular Routes used in published research
- FDA
- Not approved
- Other approvals
-
- Russia — Deltaran® intranasal (registered 2016) for stress-related states and alcohol withdrawal
- WADA
- Not on the Prohibited List
Sequence
Overview
Delta sleep-inducing peptide is a nonapeptide isolated from rabbit cerebral venous blood and characterized in 1977, named for its apparent delta-sleep-promoting effect. Its natural role remains unclear, and controlled human trials found weak or inconsistent effects on sleep.
Research status Small double-blind placebo-controlled insomnia trials (1980s-1992) with weak or inconsistent results; registered in Russia as Deltaran (intranasal) for stress-related states and alcohol withdrawal
Mechanism
Effects reported in research
Reported outcomes, not promises. Some come from controlled human trials; others may be from smaller or preclinical studies — check the studies below.
- Delta-sleep promotion reported in early animal studies
- Shorter sleep latency in one small controlled insomnia trial
- Reported effects on stress-related hormones (mostly animal data)
- Studied for stress-related states and alcohol withdrawal
Safety & unknowns
Human safety data are limited to small trials from the 1980s-1990s. Rapidly degraded by blood peptidases. Not FDA-approved. Registered in Russia as Deltaran® intranasal (2016).
Unknowns. Trial safety data apply to the populations, formulations and conditions studied.
Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.
Studies [1]
- Clinical trial 1992
Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study
In a double-blind, placebo-controlled, matched-pairs study of 16 chronic insomniacs, intravenous DSIP gave slightly higher sleep efficiency and shorter sleep latency, but effects were weak and subjective sleep quality did not change; the authors concluded short-term DSIP is unlikely to be of major benefit.
Status sources
Sources behind the tier, regulatory status, sequence and dates on this page.
- PubChem CID 68816 — Emideltide (DSIP) pubchem.ncbi.nlm.nih.gov
- Bes et al., Neuropsychobiology 1992 (double-blind trial) pubmed.ncbi.nlm.nih.gov
- Schoenenberger & Monnier, PNAS 1977 (characterization) pubmed.ncbi.nlm.nih.gov
- RLS drug register (Russia) — Deltaran rlsnet.ru
- WADA Prohibited List 2026 wada-ama.org
Cite this entry
peptidemeta. (2026). DSIP. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/dsip/
@misc{peptidemeta-dsip,
title = {DSIP},
author = {{peptidemeta}},
year = {2026},
howpublished = {\url{https://peptidemeta.com/p/dsip/}},
note = {Accessed 2026-11-08}
} Accessed date reflects when you opened this page. Cite primary studies for scientific claims.